

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



4th August, 2015.

To,
Mrs. S. Subramanian. DCS-CRD
The Secretary
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd,
"Exchange Plaza", C-1, Block - G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051.

Ref: Compliance of Clause 41 of the Listing Agreement

Script Code: 532637

Symbol: MANGALAM

Dear Sir/Madam,

**Sub: Unaudited Financial Results for the quarter
ended 30th June, 2015.**

In terms of Clause 41 of the Listing Agreement(s), enclose please find herewith Unaudited Financial Results for the quarter ended 30th June, 2015 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on 4th August, 2015 at Mumbai along with Limited Review Report of the said period.


Further please note that the Company has made necessary arrangement to publish the same in the newspaper as required under the Listing Agreement.

Please take note of the same on your record.

Thanking you,

Yours faithfully,

For MANGALAM DRUGS & ORGANICS LTD.


(Shri.GOVARDHAN M. DHOOT)
DIRECTOR



Works: at Vapi (Gujarat) India • E-Mail : contactus@mangalamdrugs.com • Website : <http://www.mangalamdrugs.com>

A. Un-Audited Financial Results for the Quarter ended 30th June 2015

(Rs. in Lacs)

Sr. No.	Particulars	3 Months ended 30.06.2015 (Unaudited)	Corresponding 3 months ended 30.06.2014 (Unaudited)	3 Months ended 31.03.2015 (Audited) (Refer Note No. 2)	Year Ended 31.03.2015 (Audited)
1	Sales/Income from operation(Net of Excise duty)	6956.09	3855.81	8039.31	22058.39
2	Other Operating Income	2.72	7.74	(481.50)	7.47
3	Total Net Income from Operation	6958.81	3863.55	7557.81	22065.86
4	Expenditure				
	(a) Increase / decrease in stock in trade & work in progress	751.76	(152.16)	(1297.80)	(745.54)
	(b) Consumption of raw materials	4376.72	2765.71	6917.90	16324.04
	(c) Employees Cost	304.75	253.18	274.62	1095.20
	(d) Depreciation	108.25	106.90	114.60	415.40
	(e) Other expenditure	880.23	641.06	1060.01	3352.68
	(f) Total	6421.71	3614.69	7069.33	20441.78
5	Profit/(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	537.10	248.86	488.48	1624.08
6	Other income	70.55	2.19	0.29	5.17
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	607.65	251.05	488.77	1629.25
8	Finance Cost	232.39	271.35	212.63	1028.37
9	Profit/(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	375.26	(20.30)	276.14	600.88
10	Exceptional Items	0.00	0.00	0.00	0.00
11	Profit/(+)/Loss(-) before Tax (9-10)	375.26	(20.30)	276.14	600.88
12	Tax Expenses(Incl Deferred Tax)	70.00	0.00	(73.24)	(13.24)
13	Net Profit/(+)/Loss(-) after Tax (11-12)	305.26	(20.30)	349.38	614.12
14	Extraordinary Items	0.00	0.00	0.00	0.00
15	Net Profit/(+)/Loss(-) for the period(13-14)	305.26	(20.30)	349.38	614.12
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	1618.59	1618.59
13	Earning per share (EPS)				
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.32	(0.15)	2.65	4.66
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.32	(0.15)	2.65	4.66
14	Non Promoters Shareholding				
	- Number of shares	7619615	7628115	7628115	7628115
	- Percentage of shareholding	57.82	57.88	57.88	57.88
15	Promoters and Promoter group Shareholding				
	a) Pledged/ Encumbered				
	Number of Shares	4050133	5491228	4050133	4050133
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	72.86	98.94	72.97	72.97
	Percentage of Shares (as a % of the total share capital of the company)	30.73	41.67	30.73	30.73
	b) Non-encumbered				
	Number of Shares	1508500	58905	1500000	1500000
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	27.14	1.06	27.03	27.03
	Percentage of Shares (as a % of the total share capital of the company)	11.45	0.45	11.39	11.39
16	Investors Complaints :	3 Months ended 30.06.2015			
	Pending at the Beginning of the Quarter	Nil			
	Received during the Quarter	1			
	Disposed of during the Quarter	1			
	Remaining unresolved at the end of the Quarter	Nil			

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 4th August, 2015
- The financial results for the quarter ended 31st March 2015 are balancing figures between audited results for the full financial year and published year to date figure upto the third quarter of the relevant financial year.
- As per the requirement of Schedule II of the Companies Act 2013, the company has charged depreciation based on the useful lives as prescribed under the Schedule. Consequently depreciation charge for the Quarter Ended 30th June 2015 is increased by Rs.4.39 Lacs.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirement of Accounting Standard(AS-17) "Segment Reporting" is not applicable
- Previous year figures are regrouped wherever necessary.

Place: Mumbai
Date: 04.08.2015

For MILWANI ASSOCIATES
Chartered Accountants

(CA Rakesh K. Milwani) Proprietor
Membership No.: 36099
F.R.N.:106405W

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot)
DIRECTOR



18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.

Tel.: 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

To
The Secretary
Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at Rupam Building, 3rd Floor, 239 P.D'Mello Road, Near GPO, Mumbai - 400 001; for the quarter ended 30th June, 2015 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Mumbai

Date : 4th August, 2015.

(*Rakesh K. Milwani*)
(RAKESH K. MILWANI)

PROPRIETOR: MILWANI ASSOCIATES

Membership No.36099

Firm Registration No.106405W

